Effect of squill oxymel in control of mild to moderate fatty liver
Not Applicable
Recruiting
- Conditions
- fatty liver.k75.8
- Registration Number
- IRCT201705261165N20
- Lead Sponsor
- Vice chancellor for research Baqiyatallah University of medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
To Sign the consent form Knowingly
patients be suffered from mild to moderate fatty liver According to the ultrasound result.
Exclusion criteria:
Off treatment for more than a week
Progression of Fatty liver disease
Person is pregnant or lactating
Allergic reactions to herbal blend
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvment of quality of life. Timepoint: at baseline and 2 month after intervention. Method of measurement: quality of life questionnaire.;FBS. Timepoint: at baseline and 2 month after intervention. Method of measurement: mg/dl.;Triglycerides. Timepoint: at baseline and 2 month after intervention. Method of measurement: mg/dl.;Cholesterol. Timepoint: at baseline and 2 month after intervention. Method of measurement: mg/dl.;Hdl. Timepoint: at baseline and 2 month after intervention. Method of measurement: mg/dl.;Ldl. Timepoint: at baseline and 2 month after intervention. Method of measurement: mg/dl.;Alt. Timepoint: at baseline and 2 month after intervention. Method of measurement: iu/l.;Ast. Timepoint: at baseline and 2 month after intervention. Method of measurement: iu/l.;Alp. Timepoint: at baseline and 2 month after intervention. Method of measurement: iu/l.;Grade of fatty liver. Timepoint: at baseline and 2 month after intervention. Method of measurement: sonography.
- Secondary Outcome Measures
Name Time Method Bmi. Timepoint: at baseline and 2 month after intervention. Method of measurement: kg/m2.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does squill oxymel employ to reduce hepatic steatosis in NAFLD patients (IRCT201705261165N20)?
How does squill oxymel compare to vitamin E and pioglitazone in improving NAFLD fibrosis scores (IRCT201705261165N20)?
Which biomarkers correlate with therapeutic response to squill oxymel in non-alcoholic steatohepatitis (NASH) subtypes?
What adverse effects of squill oxymel on liver enzymes require monitoring in mild to moderate fatty liver trials?
Are there synergistic effects when combining squill oxymel with berberine or silymarin for NAFLD treatment (IRCT201705261165N20)?